<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>治疗NASH，泛PPAR激动剂达到多项2b期临床终点 | 极客快訊</title><meta property="og:title" content="治疗NASH，泛PPAR激动剂达到多项2b期临床终点 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/f831200588034be289ddd37a18d19c6b"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/3ff4b7b.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/3ff4b7b.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/3ff4b7b.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/3ff4b7b.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/3ff4b7b.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/3ff4b7b.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/3ff4b7b.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/3ff4b7b.html><meta property="article:published_time" content="2020-10-29T20:57:49+08:00"><meta property="article:modified_time" content="2020-10-29T20:57:49+08:00"><meta name=Keywords content><meta name=description content="治疗NASH，泛PPAR激动剂达到多项2b期临床终点"><meta name=author content="极客快訊"><meta property="og:url" content="/cn/%E7%A7%91%E5%AD%A6/3ff4b7b.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快讯 Geek Bank</a></h1><p class=description>为你带来最全的科技知识 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>治疗NASH，泛PPAR激动剂达到多项2b期临床终点</h1></header><date class="post-meta meta-date">2020-10-29</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E5%AD%A6.html>科学</a></span></div><div class=post-content><div><p><span>▎药明康德内容团队编辑</span></p><p>日前，Inventiva公司宣布，该公司开发的泛PPAR激动剂lanifibranor，在治疗非酒精性脂肪性肝炎（NASH）的2b期临床试验中达到试验的主要终点和多个关键性次要终点。新闻稿指出，这是目前唯一同时满足美国FDA和欧盟EMA为加速NASH药物批准设立的双重组织学终点的在研疗法。<br></p><p><div class="pgc-image pgc-card-fixWidth"><div class="pgc-img-wrapper ttcore-relative"><img alt=治疗NASH，泛PPAR激动剂达到多项2b期临床终点 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/f831200588034be289ddd37a18d19c6b></div></div></p><p><br>NASH是一种由于在肝脏中脂肪过度积累导致的渐进性肝病，会导致患者肝脏出现慢性炎症，触发渐进性肝纤维化，肝硬化，最终导致肝功能衰竭、癌症和患者死亡。晚期纤维化患者与肝脏相关的死亡率显著升高。<br>为了加快治疗NASH疗法的开发，美国FDA在2018年发表了新的药物研发指南，指出开发NASH创新疗法时，临床试验中可以使用肝组织学终点，FDA认定的两种组织学终点为：</p><p><br>1. 脂肪性肝炎症状得到缓解，同时肝脏纤维化程度没有恶化。2. 肝脏纤维化程度得到缓解，同时脂肪性肝炎症状没有恶化。</p><p><br>Lanifibranor是一款处于临床开发阶段的泛PPAR激动剂，它对PPARα和PPARδ产生均衡的激活，并且能够部分激活PPARγ。它可以通过多种机制改善NASH患者的症状。<br></p><p><br></p><p><div class="pgc-image pgc-card-fixWidth"><div class="pgc-img-wrapper ttcore-relative"><img alt=治疗NASH，泛PPAR激动剂达到多项2b期临床终点 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/1b04f11983fc4dcf8b7328aad6675332></div></div></p><p>▲Lanifibranor的作用机制针对NASH的多种关键特征（图片来源：Inventiva官网）</p><p><br></p><p>NATIVE是一项随机双盲，含安慰剂对照的2b期临床试验，NASH确诊患者接受了两种不同剂量的lanifibranor或安慰剂的治疗。试验结果表明，在这项为期24周的临床试验中，lanifibranor达到试验的主要终点。在接受剂量为1200 mg/day的lanifibranor治疗的意向治疗（ITT）患者群中，评估肝细胞炎症和肝细胞气球样变（hepatocellular ballooning）的SAF评分与基线相比，显著降低（同时肝纤维化程度没有恶化）。Lanifibranor治疗组（1200 mg/day）的患者中49%达到这一终点，安慰剂组的数值为27%（p=0.004）。</p><p><br><div class="pgc-image pgc-card-fixWidth"><div class="pgc-img-wrapper ttcore-relative"><img alt=治疗NASH，泛PPAR激动剂达到多项2b期临床终点 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/0e4bc0fcaf2d41bcbeab9ee522fadc3d></div></div></p><p>▲Lanifibranor的主要临床终点数据（图片来源：Inventiva官网）</p><p><br>同时，lanifibranor还达到多个关键性次要终点，包括在1200 mg/day剂量组中达到改善纤维化至少一级的同时保持NASH症状不恶化。</p><p><br></p><p>Inventiva公司表示，基于公布的顶线结果，该公司已决定将这一临床研究项目推进到关键性3期临床阶段。该公司将与FDA和EMA进行讨论，确定相关临床试验的设计。Inventiva同时计划在今年11月的医学会议上汇报这一临床试验结果。<br></p><p><br></p><p>参考资料：</p><p>[1] Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH). Retrieved June 16, 2020, fromhttps://www.globenewswire.com/news-release/2020/06/15/2048284/0/en/Inventiva-s-lanifibranor-meets-the-primary-and-key-secondary-endpoints-in-the-Phase-IIb-NATIVE-clinical-trial-in-non-alcoholic-steatohepatitis-NASH.html</p><p><br></p><p>注：本文旨在介绍医药健康研究进展，不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。</p></div></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'治疗','NASH','PPAR'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>